Advertisement

Der Schmerz

, Volume 10, Issue 5, pp 261–268 | Cite as

Substanz P, Somatostatin und monoaminerge Transmitter in der Zerebrospinalflüssigkeit von Patienten mit chronischer idiopathischer Trigeminusneuralgie

  • M. Strittmatter
  • M. Grauer
  • G. Hamann
  • C. Fischer
  • K. H. Hoffmann
  • F. Blaes
  • K. Schimrigk
  • E. Isenberg
Originalien

Zusammenfassung

Bei der Trigeminusneuralgie werden periphere und zentrale Entstehungsmechanismen diskutiert. Daher wurden bei 16 Patienten (53,3±8,3 Jahre) mit einer idiopathischen Trigeminusneuralgie in der Zerebrospinalflüssigkeit (CSF) die Neuropeptide Substanz P und Somatostatin, die Neurotransmitter Noradrenalin und Adrenalin sowie die Metaboliten Homovanillinmandelsäure (HVA), Vanillinmandelsäure (VMA) und 5-Hydroxyindoleessigsäure (5-HIAA) bestimmt. Während die Substanz P in der CSF signifikant (p<0,01) erhöht gefunden wurde, war das Somatostatin gegenüber den Kontrollpersonen signifikant erniedrigt (p<0,05). Noradrenalin (p<0,01), 5-HIAA (p<0,01), HVA (p<0,05) und VMA (p<0,05) waren signifikant erniedrigt. Während die Erhöhung der Substanz P einen Hinweis auf eine lokal beschränkte neurogene Entzündung im trigemino-vaskulären System geben könnte, spricht die Reduktion monoaminerger Transmitter für eine zentral gestörte Schmerzmodulation. Diese scheint mit zunehmender Krankheitsdauer und begleitender Depression stärker zu werden. Die zahlreichen Korrelationen der Neuromediatoren untereinander, insbesondere auch zwischen den Neuropeptiden und den Klassischen Neurotransmittern, sprechen für komplexe neurochemische Interaktionen im Rahmen der Schmerzentstehung.

Schlüsselwörter

Trigeminusneuralgie CSF Neurotransmitter Substanz P Somatostatin 

Substance P, somatostatin and monoaminergic transmitters in the cerebrospinal fluid of patients with chronic idiopathic trigeminal neuralgia

Abstract

The etiology of trigeminal neuralgia is unknown, but both peripheral and central causes have been suggested. To investigate the role of central neurochemical mechanisms we measured epinephrine, norepinephrine and their breakdown product, vanilly mandelic acid (VMA), in the cerebrospinal fluid (CSF) of 16 patients (53.3±8.3 years) suffering from trigeminal neuralgia. As markers for the dopaminergic system, we determined CSF levels of dopamine and its metabolite homovanillic acid (HVA). As a marker for the serotonergic system, we measured CSF levels of serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA). In addition, levels of the neuropeptides substance P and somatostatin were determined. The concentration of norepinephrine (P<0.01), VMA (P<0.05) and HVA (P<0.05) were significantly decreased in patients with trigeminal neuralgia and correlated with the duration of the disease and depression scores. 5-HIAA was also significantly decreased (P<0.05) compared to control patients. Whereas substance P was significantly elevated (P<0.05), somatostatin was significantly decreased (P<0.05). Various correlations between the classical neurotransmitters and the neuropeptides could be established. We hypothesize than the sum of complex neurochemical changes plays a role in the etiology of trigeminal neuralgia, which can be separated in local and more central proceedings. The increase in substance P, a major nociceptive neuromodulator, supports the concept of a local neurogenic inflammation, possibly located in the trigeminovascular system. Depending on the duration of the disease and depression, the loss of serotonergic, dopaminergic and noradrenergic innervation seems to reflect more central changes, possibly due to alterations in their antinociceptive descending pathways.

Key words

Trigeminal neuralgia Neurotransmitters CSF Substance P Somatostatin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Almay BG, Johansson F, Von Korning L (1988) Substance P in CSF of patients with chronic pain syndromes Pain 33: 3CrossRefPubMedGoogle Scholar
  2. 2.
    Almay GL, Haggendahl J, Von Knorning L, Oreland L (1987) 5-HIAA and HVA in CSF in patients with idiopathic pain disorders. Biol Psychiatry 22: 403CrossRefPubMedGoogle Scholar
  3. 3.
    Asberg M, Thoren P, Traskman L (1976) Serotonin depression: a biochemical subgroup within the affective disorders? Science 191: 478CrossRefPubMedGoogle Scholar
  4. 4.
    Barker FG, Janetta PJ, Bissonette DJ, Larkins MV, Dong Jho H (1996) The long-term outcome of mikrovascular decompression for trigeminal neuralgia. N Engl J Med 334: 1077CrossRefPubMedGoogle Scholar
  5. 5.
    Bouckoms AJ, Poletti CH, Sweet HW, Carr D, Keith D (1991) Trigeminal facial pain: a model of peptides and monaamines in intracerebral cerebrospinal fluid. Agressologic 32: 271Google Scholar
  6. 6.
    Bouckoms AJ, Sweet WH, Poletti C, Lavori P, Carr D, Matson W, Garnache P, Aronin N (1992) Monoamines in the brain cerebrospinal fluid of facial pain patients. A nesth Prog 39: 201Google Scholar
  7. 7.
    Brodin E, Gazelius JM, Lundberg JM, Olgart L (1981) Substance P in trigeminal nerve endings: occurence and release. Acta Physiol Scand 111: 501CrossRefPubMedGoogle Scholar
  8. 8.
    Calvin WH, Loeser JD, Howe JF (1977) A neurophysiological theory for the pain mechanism of tic douloreux. Pain 3: 147CrossRefPubMedGoogle Scholar
  9. 9.
    Coderre TJ, Katz J, Vaccarino AL, Melzack R (1993) Contribution of central plasticity to pathological pain: review of clinical and experimental evidence. Pain 52: 259CrossRefPubMedGoogle Scholar
  10. 10.
    Dray A, Urban L, Dickenson A (1994) Pharmacology of chronic pain. TIPS 15: 190PubMedGoogle Scholar
  11. 11.
    France R (1987) CSF monoamine metabolites in chronic pain. Pain 31: 189CrossRefPubMedGoogle Scholar
  12. 12.
    Gaynor PJ, Lookingland KJ, Tucker HA (1995) 5-Hydroxytryptaminergic receptorstimulated growth hormone secretion occurs independently of changes in peripheral somatostatin concentration. Proc Soc Exp Biol Med 209: 79CrossRefPubMedGoogle Scholar
  13. 13.
    Gazelius B, Brodin E, Olgart L, Panopoulos P (1981) Evidence that substance P is a mediator of antidromic vasodilatation using somatostatin as a release inhibitor. Acta Physiol Scand 113: 155CrossRefPubMedGoogle Scholar
  14. 14.
    Ghia JN, Mueller RA, Duncan GH (1981) Serotonergic activity in man as a function of pain, pain mechanisms, and depression. Anesth Analg 60: 854CrossRefPubMedGoogle Scholar
  15. 15.
    Glover V, Jarman J, Sander M (1993) Migraine and depression: biological aspects. J Psychiatr Res 27: 223CrossRefPubMedGoogle Scholar
  16. 16.
    Goadsby PJ, Edvinsson L (1994) Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies. Brain 117: 427CrossRefPubMedGoogle Scholar
  17. 17.
    Goadsby PJ, Edvinsson L, Ekman R (1988) Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol 23: 193CrossRefPubMedGoogle Scholar
  18. 18.
    Goadsby PJ, Edvinsson L (1993) The trigeminovascular system and migraine: studies characterizing cerebrosvascular and neuropeptide changes seen in humane and cats. Ann Neurol 33: 48CrossRefPubMedGoogle Scholar
  19. 19.
    Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Hamlin PJ, King TT (1992) Neurovascular compression in trigeminal neuralgia: a clinical and anatomical study. J Neurosurg 76: 948CrossRefGoogle Scholar
  21. 21.
    Headache Classification Committee of the International Headache Society (1988) Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 8: 1CrossRefGoogle Scholar
  22. 22.
    Jensen K, Tuxen C, Pedersen-Bjergaard U, Jansen I (1991) Pain, tenderness, wheal and flare induced by substance P, bradykinin and 5-hydroxytryptamine in humane. Cephalalgia 11: 175CrossRefPubMedGoogle Scholar
  23. 23.
    Kwiat GC, Basbaum AI (1992) The origin of brainstem noradrenergic and serotonergic projections to the spinal cord dorsal horn in the rat. Somatosens Mot Res 9: 157CrossRefPubMedGoogle Scholar
  24. 24.
    Lechin F, Van der Djis B, Lechin ME, Amat J, Lechin AE, Cabera A, Gomez, F, Acosta E, Arocha L, Villa S (1989) Pimozide therapy for trigeminal neuralgia. Arch Neurol 46: 960CrossRefPubMedGoogle Scholar
  25. 25.
    Loeser JD (1994) The douloureux and atypical face pain. In: Wall DW, Melzack R (eds) Textbook of pain. Churchill Livingstone, London New York Tokyo, p 699Google Scholar
  26. 26.
    Mayberg MR, Zervas NT, Noskowitz MA (1984) Trigeminal projections to supratentorial pial and dural blood vessels in cats demonstrated by horseradish peroxidase histochemistry. J Comp Neurol 223: 46CrossRefPubMedGoogle Scholar
  27. 27.
    Meany JFM, Eldridge PR, Dunn LT, Nixon TE, Whitehouse GH, Miles JB (1995) Demonstration of neurovascular compression in trigeminal neuralgia with magnetic resonance imaging. Comparison with surgical findings in 52 consecutive operative cases. J Neurosurg 83: 799CrossRefGoogle Scholar
  28. 28.
    Melzack R (1975) The McGill Pain Questionnaire: major properties and scoring methods. Pain 1: 277CrossRefPubMedGoogle Scholar
  29. 29.
    Melzack R (1987) The short-form McGill Questionnaire. Pain 30: 191CrossRefPubMedGoogle Scholar
  30. 30.
    Melzack R, Katz J (1994) Pain measurements in persons in pain. In: Wall PD, Melzack R (eds) Textbook of pain. Churchill Livingstone, p 337Google Scholar
  31. 31.
    Mendoza N, Illingworth RD (1995) Trigeminal neuralgia treated by microvascular decompression: a long-term follow-up study. Br J Neurosurg 9: 13CrossRefPubMedGoogle Scholar
  32. 32.
    Moskowitz MA (1990) Basic mechanisms in vascular headache. Neurol Clin 8: 801PubMedGoogle Scholar
  33. 33.
    Moskowitz MA (1993) Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology 43: 16Google Scholar
  34. 34.
    Myers RD (1995) Neuroactive peptides: unique phases in research on mammalian brain over three decades. Peptides 15: 367CrossRefGoogle Scholar
  35. 35.
    Pedersen-Bjergaard U, Nielsen LB, Jensen K, Edvinsson L, Jansen I, Oelsen J (1989) Algesia and local responses induced by neurokinin A and substance P in human skin and temporal muscle. Peptides 10: 1147CrossRefPubMedGoogle Scholar
  36. 36.
    Pilowsky PM, Llewellyn-Smith IJ, Minson JB, Arnolda LF, Chalmers JP (1995) Substance P and serotonergic inputs to sympathetic preganglionic neurons. Clin Exp Hypertens 17: 335CrossRefPubMedGoogle Scholar
  37. 37.
    Rang HP, Bevan S, Dray A (1991) Chemical activation of nociceptive peripheral neurones. Br Med Bull 47: 534CrossRefPubMedGoogle Scholar
  38. 38.
    Rosen A, Frank J, Brodin E (1995) Effects of acute systemic treatment with 5-HT-uptake blocker alaproclate on tissue levels and release of substance P in rat periaqueductal grey. Neuropeptides 28: 317CrossRefPubMedGoogle Scholar
  39. 39.
    Sidebottom A, Maxwell S (1995) The medical and surgical management of trigeminal neuralgia. J Clin Pharm Ther 20: 31CrossRefPubMedGoogle Scholar
  40. 40.
    Stein C, Mendel G (1988) The German counterpart to McGill Pain Questionnare. Pain 23: 251CrossRefGoogle Scholar
  41. 41.
    Strittmatter M, Hamann G, Grauer M, Fischer C, Blaes F, Hoffmann KH, Schimrigk K (1996) Altered activity of the sympathetic nervous system and changes in the balance of hypophyseal, pituitary and adrenal hormones in patients with cluster headache. Neuroreport 7: 1229CrossRefPubMedGoogle Scholar
  42. 42.
    Strittmatter M, Hamann G, Blaes F, Grauer M, Fischer C, Hoffmann KH (1996) Reduzierte Aktivität des sympathischen Nervensystems während der Clusterperiode des Cluster-Kopf-schmerzes. Schweiz Med Wochenschr 126: 1054PubMedGoogle Scholar
  43. 43.
    Uddman R, Edvinsson L, Jansen I, Stiernholm P, Jensen K, Olesen J, Sundler F (1986) Peptide-containing nerve fibres in human extracranial tissue: a morphological basis for neuropeptide involvement in extracranil pain. Pain 27: 391CrossRefPubMedGoogle Scholar
  44. 44.
    Umehara F, Kamishisma K, Kashio N, Jamaguchi K, Sakimoto T, Osame M (1995) Magnetic resonance tomographic angiography: diagnostic value in trigeuminal neuralgia. Neuroradiology 5: 353CrossRefGoogle Scholar
  45. 45.
    Urculo E, Martinez L, Arazola M, Ramirez P (1995) Macroscopic effects of percutaneous trigeminal ganglion compression (Mullan’s technique): an anatomical study. Neurosurgery 36: 776CrossRefPubMedGoogle Scholar
  46. 46.
    Zimmermann M (1995) Neurobiologie des Schmerzsystems. Neuroforum 1: 32Google Scholar
  47. 47.
    Zimmermann M (1991) Central nervous mechanisms modulating pain-related information: do they become deficient after lesions of the peripheral or central nervous system? In: Casey KL (ed) Pain and central nervous system disease: the central pain syndromes Raven Press, New York, p 183Google Scholar

Copyright information

© Springer-Verlag 1996

Authors and Affiliations

  • M. Strittmatter
    • 1
  • M. Grauer
    • 1
  • G. Hamann
    • 1
  • C. Fischer
    • 1
  • K. H. Hoffmann
    • 1
  • F. Blaes
    • 1
  • K. Schimrigk
    • 1
  • E. Isenberg
    • 2
  1. 1.Abteilung NeurologieUniversität des SaarlandesHomburg
  2. 2.Abteilung UrologieUniversität des SaarlandesHomburg

Personalised recommendations